We were able to identify a potential triggering factor of pituitary apoplexy in 43 patients (42.9%), of whom, 15 patients (15.3%) used therapeutic anticoagulant treatment, 4 (4.1%) patients used a GnRH agonist for the treatment of prostate cancer and 11 patients (11.2%) used a dopamine agonist during onset of apoplexy symptoms. The gene discussed is GNRH1; the disease is prostate carcinoma.